AstraZeneca

News

AstraZeneca on course to long term growth, says CEO

AstraZeneca’s CEO Pascal Soriot has said the company has returned to long-term growth following a difficult period where patents on key products expired.

News

AZ sells rights to three older drugs to Covis for $350m

AstraZeneca has agreed to sell rights to three older drugs for asthma and rhinitis to Covis Pharma for at least $350 million.

News

Grünenthal buys certain rights to AZ’s Nexium and Vimovo for...

AstraZeneca has agreed to sell some of the rights to its drugs Nexium and Vimovo to Grünenthal for an upfront payment of $922 million.

News

AZ to file potential blockbuster potassium drug in Asia

AstraZeneca is planning filings of its high potassium drug Lokelma in Asia, following supportive trial findings.

News

Innate Pharma gains rights to AZ's recently approved leukaem...

France’s Innate Pharma has gained rights to AstraZeneca's recently approved leukaemia drug Lumoxiti, in a deal that expands a collaboration that began more than three years ago.

News

AZ/Merck & Co's Lynparza scores huge ovarian cancer win

AstraZeneca and Merck & Co’s Lynparza (olaparib) has massively reduced the risk of BRCA-mutated ovarian cancer progressing in patients who have just been treated with chemo, in trial re

AstraZeneca on course to long term growth, says CEO

AZ sells rights to three older drugs to Covis for $350m

Grünenthal buys certain rights to AZ’s Nexium and Vimovo for...

AZ to file potential blockbuster potassium drug in Asia

Innate Pharma gains rights to AZ's recently approved leukaem...

AZ/Merck & Co's Lynparza scores huge ovarian cancer win

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

AstraZeneca

Editor's Picks